Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Remoxy Time-Release Oxycodone Phase III Trial Planned For Year-End

  • News

Executive Summary

Pain Therapeutics plans to initiate a Phase III trial for Remoxy, its time-release oxycodone, around year-end

You may also be interested in...



Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs

Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies

Pain Therapeutics Touts Naltrexone Safety Profile Over Marketed IBS Drugs

Pain Therapeutics believes its low-dose oral naltrexone will offer a more positive risk-benefit profile and broader efficacy compared to marketed irritable bowel syndrome therapies

OxyContin Generics From Endo And Teva Will Include Risk Management Plans

Risk management programs for Endo's and Teva's generic versions of OxyContin reflect differences in the nature of generic marketing compared to that for branded drugs

Table

View full table

Topics

Tags:
BioPharmaceutical
Latest Headlines

Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

See All
UsernamePublicRestriction

Register

PS044299

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By